Solid lipid nanoparticles reduce systemic toxicity of docetaxel: Performance and mechanism in animal

References

• Ardavanis A, Tryfonopoulos D, Yiotis I, Gerasimidis G, Baziotis N, Rigatos G. 2004. Non-allergic nature of docetaxel-induced acute hypersensitivity reactions. Anticancer Drugs 15(6):581–585.
   PubMed Web of Science ®Google Scholar
• Baker J, Ajani J, Scotté F, Winther D, Martin M, Aapro MS, von Minckwitz G. 2009. Docetaxel-related side effects and their management. Eur J Oncol Nurs 13(1):49–59.
   PubMedGoogle Scholar
• Boczkowski J, Hoet P. 2010. What's new in nanotoxicology? Implications for public health from a brief review of the 2008 literature. Nanotoxicology 4(1):1–14.
   PubMedGoogle Scholar
• Chen J, Dong X, Zhao J, Tang G. 2009. In vivo acute toxicity of titanium dioxide nanoparticles to mice after intraperitioneal injection. J Appl Toxicol 29(4):330–337.
   PubMed Web of Science ®Google Scholar
• Chen Z, Meng H, Xing G, Chen C, Zhao Y, Jia G, Wang T, Yuan H, Ye C, Zhao F, Chai Z, Zhu C, Fang X, Ma B, Wan L. 2006. Acute toxicological effects of copper nanoparticles in vivo. Toxicol Lett 163(2):109–120.
   PubMed Web of Science ®Google Scholar
• Engels FK, Mathot RA, Verweij J. 2007. Alternative drug formulations of docetaxel: A review. Anticancer Drugs 18(2):95–103.
   PubMed Web of Science ®Google Scholar
• Esmaeili F, Dinarvand R, Ghahremani MH, Ostad SN, Esmaily H, Atyabi F. 2010. Cellular cytotoxicity and in-vivo biodistribution of docetaxel poly(lactide-co-glycolide) nanoparticles. Anticancer Drugs 21(1):43–52.
   PubMedGoogle Scholar
• Esmaeili F, Ghahremani MH, Ostad SN, Atyabi F, Seyedabadi M, Malekshahi MR, Amini M, Dinarvand R. 2008. Folate-receptor-targeted delivery of docetaxel nanoparticles prepared by PLGA-PEG-folate conjugate. J Drug Target 16(5):415–423.
   PubMedGoogle Scholar
• Estella-Hermoso de Mendoza A, Campanero MA, Mollinedo F, Blanco-Prieto MJ. 2009. Lipid nanomedicines for anticancer drug therapy. J Biomed Nanotechnol 5(4):323–343.
   PubMedGoogle Scholar
• Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, Richie JP, Langer R. 2006. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA 103(16):6315–6320.
   PubMed Web of Science ®Google Scholar
• Gao Y, Chen L, Gu W, Xi Y, Lin L, Li Y. 2008. Targeted nanoassembly loaded with docetaxel improves intracellular drug delivery and efficacy in murine breast cancer model. Mol Pharm 5(6):1044–1054.
   PubMedGoogle Scholar
• Hennenfent KL, Govindan R. 2006. Novel formulations of taxanes: A review. Old wine in a new bottle? Ann Oncol 17(5):735–749.
   PubMedGoogle Scholar
• Hurria A, Fleming MT, Baker SD, Kelly WK, Cutchall K, Panageas K, Caravelli J, Yeung H, Kris MG, Gomez J, Miller VA, D'Andrea G, Scher HI, Norton L, Hudis C. 2006. Pharmacokinetics and toxicity of weekly docetaxel in older patients. Clin Cancer Res 12(20 Pt 1):6100–6105.
   PubMedGoogle Scholar
• Kuderer NM, Dale DC, Crawford J, Lyman GH. 2007. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: A systematic review. J Clin Oncol 25(21):3158–3167.
   PubMed Web of Science ®Google Scholar
• Kuppens IE. 2006. Current state of the art of new tubulin inhibitors in the clinic. Curr Clin Pharmacol 1(1):57–70.
   PubMedGoogle Scholar
• Lee MK, Lim SJ, Kim CK. 2007. Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biomaterials 28(12):2137–2146.
   PubMed Web of Science ®Google Scholar
• Li JJ, Muralikrishnan S, Ng CT, Yung LY, Bay BH. 2010. Nanoparticle-induced pulmonary toxicity. Exp Biol Med 235(9):1025–1033.
   Google Scholar
• Liang G, Jia-Bi Z, Fei X, Bin N. 2007. Preparation, characterization and pharmacokinetics of N-palmitoyl chitosan anchored docetaxel liposomes. J Pharm Pharmacol 59(5):661–667.
   PubMedGoogle Scholar
• Liu J, Zahedi P, Zeng F, Allen C. 2008. Nano-sized assemblies of a PEG-docetaxel conjugate as a formulation strategy for docetaxel. J Pharm Sci 97(8):3274–3290.
   PubMed Web of Science ®Google Scholar
• Markman M. 2003. Management of toxicities associated with the administration of taxanes. Expert Opin Drug Saf 2(2):141–146.
   PubMedGoogle Scholar
• Montero A, Fossella F, Hortobagyi G, Valero V, Montero A, Fossella F, Hortobagyi G, Valero V. 2005. Docetaxel for treatment of solid tumours: A systematic review of clinical data. Lancet Oncol 6(4):229–239.
   PubMedGoogle Scholar
• Mu CF, Balakrishnan P, Cui FD, Yin YM, Lee YB, Choi HG, Yong CS, Chung SJ, Shim CK, Kim DD. 2010. The effects of mixed MPEG-PLA/Pluronic copolymer micelles on the bioavailability and multidrug resistance of docetaxel. Biomaterials 31(8):2371–2379.
   PubMedGoogle Scholar
• Puri A, Loomis K, Smith B, Lee JH, Yavlovich A, Heldman E, Blumenthal R. 2009. Lipid-based nanoparticles as pharmaceutical drug carriers: From concepts to clinic. Crit Rev Ther Drug Carrier Syst 26(6):523–580.
   PubMedGoogle Scholar
• Saloustros E, Mavroudis D, Georgoulias V. 2008. Paclitaxel and docetaxel in the treatment of breast cancer. Expert Opin Pharmacother 9(15):2603–2616.
   PubMedGoogle Scholar
• Shin HC, Alani AW, Rao DA, Rockich NC, Kwon GS. 2009. Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs. J Control Release 140(3):294–300.
   PubMedGoogle Scholar
• Stemmler J, Mair W, Stauch M, Papke J, Deutsch G, Abenhardt W, Dorn B, Kentenich C, Malekmohammadi M, Jackisch C, Leinung S, Brudler O, Vehling-Kaiser U, Stamp J, Heinemann V. 2005. High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer. Oncology 68(1):71–78.
   PubMedGoogle Scholar
• ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. 2003. Pharmacological effects of formulation vehicles: Implications for cancer chemotherapy. Clin Pharmacokinet 42(7):665–685.
   PubMed Web of Science ®Google Scholar
• Tubiana-Hulin M. 2005. How to maximize the efficacy of taxanes in breast cancer. Cancer Treat Rev 31(Suppl. 4):S3–9.
   Google Scholar
• Wang J, Zhou G, Chen C, Yu H, Wang T, Ma Y, Jia G, Gao Y, Li B, Sun J, Li Y, Jiao F, Zhao Y, Chai Z. 2007. Acute toxicity and biodistribution of different sized titanium dioxide particles in mice after oral administration. Toxicol Lett 168(2):176–185.
   PubMed Web of Science ®Google Scholar
• Wolff AC, Wang M, Li H, Pins MR, Pretorius FJ, Rowland KM, Sparano JA, Davidson NE. 2010. Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group trial E3198. Breast Cancer Res Treat 121(1):111–120.
   PubMedGoogle Scholar
• Xu Z, Chen L, Gu W, Gao Y, Lin L, Zhang Z, Xi Y, Li Y. 2009. The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomaterials 30(2):226–232.
   PubMedGoogle Scholar
• Yanasarn N, Sloat BR, Cui Z. 2009. Nanoparticles engineered from lecithin-in-water emulsions as a potential delivery system for docetaxel. Int J Pharm 379(1):174–180.
   PubMedGoogle Scholar
• Zhai G, Wu J, Xiang G, Mao W, Yu B, Li H, Piao L, Lee LJ, Lee RJ. 2009. Preparation, characterization and pharmacokinetics of folate receptor-targeted liposomes for docetaxel delivery. J Nanosci Nanotechnol 9(3):2155–2161.
   PubMedGoogle Scholar
• Zhao Y, Xing G, Chai Z. 2008. Nanotoxicology: Are carbon nanotubes safe? Nat Nanotechnol 3(4):191–192.
   PubMedGoogle Scholar
• Zheng D, Li D, Lu X, Feng Z. 2010. Enhanced antitumor efficiency of docetaxel-loaded nanoparticles in a human ovarian xenograft model with lower systemic toxicities by intratumoral delivery. Oncol Rep 23(3):717–724.
   PubMedGoogle Scholar